滑液包炎治療市場：タイプ別、薬剤タイプ別、エンドユーザー別-2025-2030年の世界予測

滑液包炎治療市場は、2023年に78億1,000万米ドルと評価され、2024年には81億4,000万米ドルに達すると予測され、CAGR 4.58％で成長し、2030年には106億9,000万米ドルに達すると予測されています。

滑液包炎治療市場には、滑液包炎（関節付近の骨、腱、筋肉などのクッションとなる小さな液体で満たされた袋）に伴う炎症や痛みを緩和することを目的としたさまざまな治療アプローチが含まれます。滑液包炎治療の必要性は、疼痛を管理し、関節のさらなる損傷を防ぐことで、患者の可動性と生活の質を維持する必要性から生じる。治療には、非ステロイド性抗炎症薬（NSAIDs）やコルチコステロイド注射などの薬物療法から、理学療法や重症の場合の手術まで、さまざまな用途があります。最終的な使用範囲は、主に病院、クリニック、整形外科や理学療法の専門センターなどのヘルスケア環境です。

市場成長に関しては、生活習慣に関連した障害の増加、高齢者人口の増加、筋骨格系の健康に対する一般市民の意識の高まりが、効果的な滑液包炎治療に対する需要を促進しています。最新のビジネスチャンスとしては、有効性と患者の回復時間という点で有望な利点を提供する、高度な生物学的療法と低侵襲外科手術の開発が挙げられます。遺伝子やバイオマーカー研究の進歩による個別化医療の革新も、個々の患者のニーズに的確に対応する標的治療の選択肢を提供する可能性があります。

しかし、高度な治療に伴う高額な費用や、長期にわたる薬物療法による副作用の可能性といった課題によって、市場の成長は阻まれています。低所得地域ではヘルスケアサービスへのアクセスが制限されていることが、さらに市場拡大を制約しています。さらに、規制上のハードルや医薬品承認のペースの遅さが、新規治療の導入を遅らせる可能性もあります。

技術革新と研究が熟している分野には、標的性と有効性を向上させるドラッグデリバリーシステムの強化、費用対効果の高い生物製剤の開発、滑液包炎の症状をモニタリング・管理するためのウェアラブルなどのデジタルヘルスソリューションの統合などがあります。また、人間工学に基づいた教育や早期介入戦略による予防医療への注力も、事業成長の重要な手段となります。同市場は、急速な技術進歩や、治療・管理戦略における学際的アプローチの統合の拡大を特徴とするダイナミックな性質を示しています。

市場力学：急速に進化する滑液包炎治療市場の主要市場インサイトを公開

滑液包炎治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の筋骨格系障害の発生率の上昇
  • 医療インフラへの投資増と相まっての意識の高まり
• 市場抑制要因
  • 医薬品承認に関する政府の厳しい規制
• 市場機会
  • 滑液包炎の診断ツールおよび治療オプションの進歩
  • 製剤開発における継続的な技術革新
• 市場の課題
  • 診断に伴う複雑さと償還政策の欠如

ポーターのファイブフォース：滑液包炎治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：滑液包炎治療市場における外部からの影響の把握

外部マクロ環境要因は、滑液包炎治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析滑液包炎治療市場における競合情勢の把握

滑液包炎治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス滑液包炎治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、滑液包炎治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨滑液包炎治療市場における成功への道筋を描く

滑液包炎治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で筋骨格系疾患の発生率が上昇
    • 意識の高まりと医療インフラへの投資の増加
  • 抑制要因
    • 医薬品の承認に関する政府の厳しい規制
  • 機会
    • 滑液包炎の診断ツールと治療オプションの進歩
    • 医薬品開発処方における継続的なイノベーション
  • 課題
    • 診断に伴う複雑さと償還ポリシーの欠如
• 市場セグメンテーション分析
  • タイプ：慢性滑液包炎は、疼痛管理とさらなる関節損傷の予防に対処する治療を好む
  • エンドユーザー：病院や診療所では、急性滑液包炎に必要な即時治療へのアクセスが容易になります。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 滑液包炎治療市場：タイプ別

• 急性滑液包炎
• 慢性滑液包炎

第7章 滑液包炎治療市場薬の種類別

• 薬物治療
  • コルチコステロイド
  • 非ステロイド性抗炎症薬（NSAID）
  • 理学療法
• 理学療法

第8章 滑液包炎治療市場：エンドユーザー別

• 病院・クリニック
• リハビリテーションセンター

第9章 南北アメリカの滑液包炎治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の滑液包炎治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの滑液包炎治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • エンド製薬、デュエクシスのジェネリック版「イブプロフェン・ファモチジン錠」を発売
  • FDA、デュシェンヌ型筋ジストロフィーの治療に革新的なコルチコステロイドを承認
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Arinna Lifesciences Ltd.
• AstraZeneca PLC
• Bioanalytical Systems, Inc.
• Bristol-Myers Squibb Company
• Crescent Formulations Pvt.Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• NIDEK CO., LTD.
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Topcon Corporation

LIST OF FIGURES

• FIGURE 1. BURSITIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. BURSITIS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BURSITIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BURSITIS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ACUTE BURSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CHRONIC BURSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. CHINA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. ITALY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ITALY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. POLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. POLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. QATAR BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. QATAR BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM BURSITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 189. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Bursitis Treatment Market was valued at USD 7.81 billion in 2023, expected to reach USD 8.14 billion in 2024, and is projected to grow at a CAGR of 4.58%, to USD 10.69 billion by 2030.

The market for bursitis treatment encompasses a range of therapeutic approaches aimed at alleviating the inflammation and pain associated with bursitis, a condition where bursae-the small, fluid-filled sacs cushioning bones, tendons, and muscles near joints-become inflamed. The necessity for bursitis treatment arises from the need to manage pain and prevent further joint damage, thereby maintaining mobility and quality of life for sufferers. Applications of treatment span from pharmacological therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections, to physical therapy and surgery in severe cases. End-use scope is primarily in healthcare settings, including hospitals, clinics, and specialized orthopedic and physiotherapy centers.

In terms of market growth, increasing incidences of lifestyle-related disorders, rising geriatric population, and greater public awareness of musculoskeletal health drive the demand for effective bursitis treatments. Latest opportunities include the development of advanced biologic therapies and minimally invasive surgical procedures that offer promising benefits in terms of efficacy and patient recovery time. Innovations in personalized medicine, driven by advances in genetic and biomarker research, may also provide targeted therapeutic options, addressing individual patient needs more precisely.

However, market growth is challenged by limitations such as the high costs associated with advanced therapies and the potential side effects of long-term pharmacological treatment. Restricted access to healthcare services in low-income regions further constrains market expansion. Additionally, regulatory hurdles and the slow pace of drug approval can delay the introduction of novel treatments.

Areas ripe for innovation and research include enhancing drug delivery systems to improve targeting and efficacy, developing cost-effective biologics, and integrating digital health solutions such as wearables for monitoring and managing bursitis symptoms. A focus on preventative care through ergonomic education and early intervention strategies also represents a significant avenue for business growth. The market displays a dynamic nature, characterized by rapid technological advancements and growing integration of interdisciplinary approaches in treatment and management strategies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bursitis Treatment Market

The Bursitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of musculoskeletal disorders globally
  • Increased awareness coupled with rising investment in health infrastructure
• Market Restraints
  • Strict government regulations regarding drug approval
• Market Opportunities
  • Advancements in diagnostic tools and treatment options in bursitis
  • Ongoing innovation in drug development formulations
• Market Challenges
  • Complexities associated with diagnostic and lack of reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Bursitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bursitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bursitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bursitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bursitis Treatment Market

A detailed market share analysis in the Bursitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bursitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bursitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bursitis Treatment Market

A strategic analysis of the Bursitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bursitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Arinna Lifesciences Ltd., AstraZeneca PLC, Bioanalytical Systems, Inc., Bristol-Myers Squibb Company, Crescent Formulations Pvt.Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., NIDEK CO., LTD., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Bursitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Acute Bursitis and Chronic Bursitis.
• Based on Drug Type, market is studied across Medication and Physical Therapy. The Medication is further studied across Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Physical Therapy.
• Based on End-User, market is studied across Hospitals & Clinics and Rehabilitation Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of musculoskeletal disorders globally
    • 5.1.1.2. Increased awareness coupled with rising investment in health infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. Strict government regulations regarding drug approval
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in diagnostic tools and treatment options in bursitis
    • 5.1.3.2. Ongoing innovation in drug development formulations
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with diagnostic and lack of reimbursement policies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Chronic bursitis prefer treatments to address pain management and prevention of further joint damage
  • 5.2.2. End-User: Hospitals and clinics offer better accessibility for the immediate care required for acute bursitis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bursitis Treatment Market, by Type

• 6.1. Introduction
• 6.2. Acute Bursitis
• 6.3. Chronic Bursitis

7. Bursitis Treatment Market, by Drug Type

• 7.1. Introduction
• 7.2. Medication
  • 7.2.1. Corticosteroids
  • 7.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.2.3. Physical Therapy
• 7.3. Physical Therapy

8. Bursitis Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Rehabilitation Centers

9. Americas Bursitis Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bursitis Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bursitis Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Endo Pharmaceuticals Introduces Generic Version of Duexis: Ibuprofen-Famotidine Tablets
  • 12.3.2. FDA Greenlights Innovative Corticosteroid for Duchenne Muscular Dystrophy Management
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Arinna Lifesciences Ltd.
• 4. AstraZeneca PLC
• 5. Bioanalytical Systems, Inc.
• 6. Bristol-Myers Squibb Company
• 7. Crescent Formulations Pvt.Ltd.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd.
• 10. GlaxoSmithKline plc
• 11. Johnson & Johnson Services, Inc.
• 12. Merck & Co., Inc.
• 13. NIDEK CO., LTD.
• 14. Novartis AG
• 15. Perrigo Company PLC
• 16. Pfizer Inc.
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Limited
• 19. Teva Pharmaceutical Industries Ltd.
• 20. Topcon Corporation